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Thirty four (34) of the fifty (50) selected Nigerian based pharmaceutical businesses, mainly acting as 
local manufacturers and major importers of medicines were interviewed using questionnaires to 
ascertain their waste management practices, knowledge of waste management policies and subjection 
to regulatory control. This study indicated that like its counterpart industry in other countries of the 
world, the Nigerian pharmaceutical industry generated both hazardous and non-hazardous wastes. 
However, the wastes were not categorized, poorly managed by 91.2% of the respondents, while 58.8% of 
the health and safety personnel had little or no modern knowledge of waste management. Furthermore, 
73.5% of the respondents claimed that they were aware of the regulatory requirements on waste, but no 
adherence was observed. The industry did not benefit from the strict supervisions of regulatory 
agencies. Pharmaceutical waste was improperly disposed and all the secondary manufacturers (79.4%) 
discharged wastewater without removal of pharmaceuticals. This study highlighted the urgent need to 
train personnel in the pharmaceutical industry and regulatory authorities. Management of waste should 
be planned, documented, implemented and sustained. 
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Four to five decades ago, the focus of developed 
countries was how to prevent industrial and domestic 
waste from entering the waterways. Treatment plants 
were employed to improve the quality of water before 
wastewater was discharged into the lakes and rivers. 
While industrial waste and domestic waste were being 
managed, pharmaceutical waste became the emerging 
contaminant as it was discovered that it was neither 
completely removed nor degraded in the treatment plants 
(Ternes, 1998; Buser et al., 1999; Stumpf et al., 1999; 
Latch et al., 2003). 
Pharmaceuticals, though used to treat and manage 
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concerns about their presence in the environment. A 
typical example is paracetamol, which is a commonly 
used over-the-counter drug that can induce liver failure 
on high doses. If dose is a determinant of the toxicity of 
drugs, are the concerns about pharmaceuticals in the 
environment misplaced when it can be argued that the 
quantities in the environment may not be at toxic levels? 
Considering the fact that wastewater is being increasingly 
recycled for agricultural use and there is increased 
pharmaceutical use and disposal in highly populated 
countries, then the health and environmental concerns 
may be justified.  
Pharmaceuticals have not only been found in waste-
water, but also in surface, ground and drinking waters 
(Jones et  al.,  2002;  Zuccato  et al.,  2006;  Castensson, 
2008; Heberer, 2002; Kümmerer, 2008; Keil et al., 2008). 
A review was written  on  the  occurrence  of  pharmaceu- 
ticals in the sewage, ground, surface and drinking waters  




(Heberer, 2002). The   studies  undertaken  in  about   ten 
countries detected more than 80 pharmaceuticals in 
sewage, ground and surface water to the level of g/L 
and traces in drinking water. One of the concerns is the 
possible impact of the accumulation of pharmaceuticals in 
humans and aquatic animals over a prolonged period as 
some of them are known to persist in the water 
environment (Hektoen et al., 1995; Selvik et al., 2002). 
Presently, the apparent major concern is the effect of 
pharmaceuticals on aquatic organisms (Sherer, 2006) as 
the extent of the impact on human is not as defined. 
Effects on aquatic organisms have been studied 
(Cleuvers, 2003; Fenske et al., 2005; Huggett et al., 
2002; Lange et al., 2001; Henschel et al., 1997; Pomati et 
al., 2004; De Lange et al., 2006) and these include 
inhibition of growth, production of stress hormone 
(abscisic acid), feminization and behavioural changes. 
Furthermore, pharmaceutical mixtures (ibuprofen, fluo-
xethin and ciprofloxacin) have been shown to cause 
mortality of fish in g/L range (Richards et al., 2004). An 
indirect effect has also been observed in a study which 
attributed diclofenac residues to the population decline of 
vultures in Pakistan (Oaks et al., 2004). 
Sources of pharmaceutical wastes include excreted 
substances, improper disposal by hospitals and patients, 
agricultural waste due to veterinary use and livestock 
feed additives (Zuccato et al., 2000; Heberer, 2002) and 
manufacturing industries. It is understood that in the 
United States, waste from the pharmaceutical industries 
are being monitored (Castensson, 2008). In fact, the 
leading international pharmaceutical industries over the 
years have made waste management part of the overall 
management system to improve their performance in the 
field of health, safety and environment.  A review on the 
pharmaceutical industries and the progress they have 
made in environmental management by generating heal-
th, safety and environment programs, preventing pollu-
tion, waste minimization, recycling and reusing of 
materials, and investing in projects and facilities to ensure 
environmental sustainability have been published (Berry 
and Rondinelli, 2000). Their annual reports can be 
obtained from their websites indicating the progress they 
have made on waste management. Some of the Indus-
tries include Merck, Eli lily, Sanofi-Aventis, AstraZeneca, 
GlaxoSmithkline, Novartis and Roche.  
In countries, such as United Kingdom, United States of 
America and Germany, the concentrations of pharma-
ceuticals in treated wastewater, surface water and ground 
water are in the range of ng/L and in some cases g/L 
(Fent et al., 2006). However, the concentrations of 
pharmaceuticals in Asian countries, such as India, were 
much higher in the range of mg/L (with ciprofloxacin 
having the highest concentration of 28 to 31 mg/L) 
(Larsson et al., 2007; Li et al., 2008). The studies by 
Larsson et al. (2007) and Li et al. (2008) buttress the 
point  that pharmaceutical  industries, especially in  deve- 





waste in the water environment. 
A report (unpublished) on the history of the 
pharmaceutical industry indicated that the advent of 
Nigerian pharmaceutical industry began with some 
multinational companies having sales outlets in the coun-
try purely to meet pharmaceutical needs. The early sixties 
saw the emergence of some tertiary manufacturers of 
pharmaceutical products. Tertiary manufacturers, then, 
were involved in the bulk importation of already 
formulated medicines to break the bulk and package 
locally. Later, indigenous secondary manufacturers began 
to emerge, but were initially limited to tableting and liquid 
mixing operations. However, the manufacturing industry 
has made some progress, though slowly. Currently, some 
companies have gone into other dosage forms such as 
creams, emulsions, liniments and sterile products. Nigeria 
is yet to have a primary manufacturer that produces bulk 
active ingredients. The existing companies that produce 
finished products today import most excipients, and all 
the active ingredients.  
Among the other challenges that face the Nigerian 
pharmaceutical industry, is the issue of pharmaceutical 
waste and its impact on the environment and public 
health. No matter the type/level of production or 
pharmaceutical business, the pharmaceutical industry 
generates pharmaceutical waste. While countries such as 
Italy (Zuccato et al., 2005; Zuccato et al., 2006), Germany 
(Ternes, 1998; Sacher et al., 2001), United States 
(Erickson, 2002), United Kingdom (Bound and Voulvoulis, 
2006; Roberts and Thomas, 2006), Taiwan (Lin and Tsai, 
2009), India (Fick et al., 2009) have been determining 
and monitoring pharmaceutical waste, there is no 
apparent indication that Nigeria is monitoring it and there 
is little or no awareness that pharmaceutical waste is an 
emerging contaminant with growing concern. If hundreds 
of tons of pharmaceutical substances enter the sewage 
treatment plant given to about 60 million people each 
year in Italy, it raises concern for Nigeria with a population 
of 150 million people. Some studies have been 
undertaken in Nigeria to assess the management of 
healthcare waste (Bassey et al., 2006; Coker et al., 2009; 
Longe and Williams, 2006; Ngwuluka, et al., 2009) and in 
sum, it can be adjudged that healthcare wastes are 
poorly managed in Nigerian hospitals. Although, some of 
the Nigerian pharmaceutical industries were started by 
some international counterparts, we hypothesized that 
the local industries fall short in management of 
pharmaceutical waste. 
Therefore, this study was undertaken to obtain data on 
pharmaceutical waste and its management from the 
pharmaceutical industries in Nigeria – the types and 
quantities of waste generated and disposed by these 
industries, in order to assess their waste management 
practices in comparison with international  standards  and 
recommendations, and to assess the awareness of the 
industries on the regulatory requirements and the impact 





MATERIALS AD METHODS 
 
The data-collection method employed in this study was the use of 
questionnaire administered through interview. The questions were 
written to meet the objectives. The fact that it was an interview 
enabled further clarifications of the questions if required by the 
respondents to assist them answer the questions appropriately. The 
key people interviewed varied from industry to industry based on 
who the industries thought were suitable to answer the questions. 
These people included quality control/assurance managers, 
regulatory officers, superintendent pharmacists and environmental 
officers. Fifty (50) industries were visited and each interview lasted 
between half an hour to one hour. The visits and interviews were 
personally undertaken by the authors. 
 
 
Structure of questionnaire  
 
The questionnaire had 10 major questions with some sub-
questions. The questions included contact details, type of business, 
installation and production capacity, list of products manufactured or 
imported, type of waste generated and quantity, waste management 
practices, personnel and training, regulatory requirements and 
management of product recall. 
 
 
Pre-testing of questionnaire 
 
The questionnaire was tested in two pharmaceutical industries in 
Jos, Plateau state, which enabled further improvement of the 





Pharmaceutical Industries in four Nigerian states - Lagos, Ogun, 
Niger and Plateau states - were visited. Lagos and Ogun states, 
located in the South-west of Nigeria, accounted for 88% of the 
industries while Niger and Plateau states located in the middle-belt 
region of the country accounted for 4 industries visited. The 




Analysis of data  
 
The data obtained following the administration of the questionnaire 
were presented in simple percentages of the numbers that 
responded to each interview question. 
 
 
RESULTS AND DISCUSSION 
 
Profiling of the pharmaceutical industries 
 
There are over 100 pharmaceutical manufacturing 
industries and major importers of medicines in Nigeria; 
though, not all are registered members of pharmaceutical 
manufacturers group of manufacturers association of 
Nigeria (PMG-MAN). It is also estimated that more than 
50% of them are situated in Lagos. This could be due to 
the proximity of the sea port  as a number  of drugs  and 
most of the raw materials are imported. Furthermore, it is 
attributed to the fact that Lagos still remains the 
commercial capital of  Nigeria.  Fifty  (50)  pharmaceutical 




industries were visited, and 34 responded to the interview 
conducted with the questionnaire. A hundred percent 
response was not achieved due to some companies' poli-
cies, protocol, unavailability of personnel appropriate for 
interview, fear of being implicated by the survey and the 
inability of the interviewer to re-visit after previous 
attempts. However, the overall percent response was 
68% which was above average. Table 1 shows percent-
tage response and their locations, while Figure 1 
categorizes the type of business practiced by 
respondents. It is over 50 years since the first 
pharmaceutical industry started in Nigeria, an exporter of 
petroleum with a good potential of developing the 
petrochemical industry for supply of raw materials; yet no 
primary pharmaceutical manufacturers exist to date. 
From Figure 1, 44.1% of the respondents were involved 
in secondary manufacturing while 38.2% were engaged 
in secondary manufacturing and finished product 
importation. The temptation for manufacturers to get 
involved in product importation from Asia, especially, is 
very high as products imported end up being cheaper due 
to lack of overhead cost. 
 
 
Generation of pharmaceutical waste and wastewater 
 
The various forms of pharmaceutical waste generated by 
the industries are depicted in Figure 2. Only 17.7% 
admitted to have had formulations that were not re-
workable, while 29.4% have had spillage of their pharma-
ceuticals. Some argued that they were manufacturing 
below installed capacity and so had no expired medicines 
except for quarantine samples. Some importers admitted 
to donating products that were close to expiry to 
physicians. 
Most of the industries import raw materials while they 
source locally in emergency. Twenty one (61.8%) admit-
ted receiving low quality active pharmaceutical ingre-
dients (APIs), while 20.6% admitted to have had expired 
APIs. Moreover, expired and low quality APIs are 
pharmaceutical wastes. Two of the respondents ex-
plained that they had expired APIs because the 
formulation of the products was discontinued. 
Most of the respondents could not ascertain the 
quantity of waste generated. However, a few were 
specific and provided documentary evidence stating that 
quantity of waste is one of the requirements of regulatory 
authorities (U.S. Code, 2006; FEPA, 1991). Other respon-
dents did not understand that it was necessary to know 
the quantity of waste generated as it would determine the 
method of disposal.  
All manufacturing pharmaceutical industries generated 
wastewater,  which   resulted   from   the  water  used  for 
process operations during manufacturing and in contact 
with intermediary, finished and/or by-products. Wastewater 
could come from the water used to clean equipment, 
pipes and floors, and would contain amongst other 
materials,   chemicals  and  active  pharmaceutical  ingre-




Table 1. Company locations and percent response. 
 
Parameter Lagos state Ogun state Niger state Plateau state Total 
Number of companies visited 40 6 3 1 50 
Number of responses 25 5 3 1 34 










dients (APIs).  
The 1990 survey conducted by U.S EPA (environmental 
protection agency) consisting of 244 chemical facilities 
estimated the average daily wastewater generation by 
pharmaceutical industries to be 266 million gallons 
(1006919538.8 L) (EPA office of compliance, 1997). 
Documentation of the quantity of wastewater is lacking in 
the Nigerian Pharmaceutical Industry. Only a few have an 
estimate of the quantity of wastewater generated daily. 
Since wastewater is generated daily and contains 
chemicals and APIs, disposal of wastewater should be of 
interest to government regulatory authorities in order to 
protect public health.  
 
 




From the survey shown in Table 2, it was obvious that 
pharmaceutical waste and wastewater were improperly 
managed and disposed by the surveyed industries.  
Three respondents stated that Lagos State Environmental 
Protection Agency (LASEPA), in the presence of National 
Agency for Food, Drug Administration and Control 
(NAFDAC) and a representative of the company, 
disposed their pharmaceutical waste. However, a visit to 
LASEPA by the authors revealed that as of the time of 
this study, only one company's waste had been disposed 
by the agency.  
LASEPA revealed how pharmaceutical waste is disposed 
by the agency. First, an industry would write stating the 
drugs or raw materials to be disposed with the quantities. 
A staff of the agency would go to assess the waste, 
container, the chemical content and the quantity; and he 
would take samples for analysis. After confirmation, the 
industry is billed depending on the weight and level of 
toxicity. The samples are taken to the laboratory to 
determine a suitable solvent that will dissolve the waste. 
The identified solvent and pharmaceutical waste is mixed 
in a mixing tank, transferred into the diluting tank where 
pH is adjusted to neutral and diluted with water before the 
liquid is flushed into the environment. The packaging 
(bottles and drums) is crushed and buried at a dump site 
while paper packaging is burnt. Finally, a certificate is 
issued with a consignment note (consignment note is 
used to prepare the certificate). After disposal, a report is 
written and signed by a representative  from  the  industry  






Figure 2. The various forms of pharmaceutical waste from the industries. (1) 
Expired dosage forms, (2) non-reworkable formulations, (3) spilled 
pharmaceuticals, (4) rejected active pharmaceutical ingredients, (5) expired 




and a senior officer from the agency. Dissolving pharma-
ceutical waste in a suitable solvent does not necessarily 
inactivate the pharmaceutical waste or their environ-
mental and human impacts.  
Some of the industries (29.4%) flushed their pharma-
ceutical waste down the drain with lots of water.  A 
section of these industries formulate antibiotics which are 
not to be discharged into drains or sewers. In fact, on no 
account should any quantity of pharmaceutical waste be 
disposed through the drain, slow moving or stagnant 
water bodies (Prüss et al. 1999). One industry permitted 
Lagos State Waste Management Authority (LAWMA) to 
dispose her pharmaceutical waste. However, LAWMA is 
equipped to manage non-hazardous waste while LASEPA 
is to manage hazardous waste.  
Mixing of waste with sand and chemical disinfection is 
usually not adequate for pharmaceuticals, chemicals and 
some types of infectious waste. Burying of 
pharmaceutical waste is improper for environmental 
reasons, which include the leaching of the waste into 
ground water and surface water (Castensson, 2008; 
Kümmerer, 2009). 
Returning materials below quality or of close expiration 
dates to suppliers may be ideal in developed countries, 
but in Nigeria where the local suppliers are not properly 
regulated and controlled, the same products could be 
repackaged and re-circulated. Re-exportation or reversed 
logistics of chemicals and pharmaceuticals out of Nigeria 
is illegal. These would lead to attempts to re-sell to 
unsuspecting customers, and in the event that they are 
unable to do so, the waste may be released into the 
environment and/or waters.  
Open air burning practiced by the industries generates 
toxic emissions into the air. Pharmaceutical waste should 
be burnt in well-constructed incinerators at recommended 
temperatures with means of controlling emissions. 
Incineration with general or infectious waste can be 
undertaken as long as the pharmaceutical waste is not 
more than 1% of the total waste to limit toxic emissions 
into the air (Prüss et al., 1999). Three respondents 
dissolved their pharmaceutical waste in an undisclosed 
solvent followed by discharge through the effluent plant. 
This method is unconventional and would lead to the 
discharge of raw pharmaceutical waste into the 
environment and waters.  
Indeed, incineration is the best method of disposing 
pharmaceutical waste. To ensure optimal combustion, it 
should be mixed with the packaging, while other 
combustible materials and infectious waste and 
combustion should be at 1000°C to burn off potentially 
toxic exhaust gases. For large pharmaceuticals, rotary 






Wastewater    treated     conventionally    or  untreated  is  




Table 2. Methods of disposal of pharmaceutical waste and wastewater by the respondents. 
 
Pharmaceutical waste Number of respondent Wastewater 
Number of 
respondent 
Flushed down the drain. 10 Not treated and discharged into the drain, canal or gutters. 11 
    
Carried away by LAWMA for 
destruction in the presence of 
company’s staff. 
1 
Not treated and discharged into the 
drain, but LASEPA often took 
samples for analysis. 
2 
    
Burnt in the presence of NAFDAC or 
LASEPA and company’s staff. 5 
Treated in a tank and analyzed by 
LASEPA before it is discharged into 
the drain. 
8 
    
Burnt on company’s volition 2 Passed through the effluent plant. 2 
    
Carted away by NAFDAC and a 
certificate was issued. 3 
Collected into a reservoir and it 
gradually sips into the soil. 2 
    
Buried within or near the premises. 2 Collected into a tank and is later used for gardening 1 
    
Tablets are mixed with sand and water, 
packed in a polythene bag and 
discarded as general waste. 
1 Flows freely into farmlands and streams around. 1 
    
Burnt within the premises with general 
waste 1   
    
Dissolved and transferred into the 
effluent plant. 3   
    
Poured into a tank, disinfected, 
allowed to stand for 2 days and 
discharged into the drain. 
1   
    
Rejected APIs returned to supplier 21   
    
The supplier is informed of the rejected 




irrelevant as the pharmaceuticals are discharged into the 
waters. Studies have shown the prevalence of antibiotic-
resistant pathogens in wastewater (Grabow and 
Prozesky, 1973; Guardabassi et al., 1998; Pruden et al., 
2006; Reinthaler et al., 2003) leading to the challenges in 
antimicrobial therapy. Guardabassi and co-workers in 
their antibiotic resistance comparative study using 
wastewater from a hospital and a pharmaceutical plant 
found out that the wastewater from the pharmaceutical 
plant had increase in the prevalence of antibiotic 
resistance among Acinetobacter species (Guardabassi et 
al., 1998). A city like Lagos with more than 40 
pharmaceutical industries may have increase in 
prevalence of antibiotic resistance as well as 
pharmaceuticals with concentrations that may be of great 
concern. The discharge of wastewater without proper 
treatment to remove pharmaceuticals may lead to 
contamination of drinking water. 
A visit to one of the environmental laboratories, 
registered with LASEPA, revealed the parameters 
analyzed in wastewater samples obtained from 
pharmaceutical industries to include chemical oxygen 
demand (COD), biological oxygen demand (BOD), trace 
heavy elements, microbiology, oil and grease, residual 
chlorine, total suspended solids (TSS), pH, conductivity 
(reactions of ions), turbidity, chloride, nutrients 
(phosphates, sulphates, nitrates) and dissolved oxygen 
(DO).     Apparently,       neither      the      presence      of  




Table 3. Performance of the industries on waste management. 
 
Criteria 
Company n = 34 
Number (%) 
Awareness of regulatory requirements 25 73.5 
Availability of company’s policy on waste 13 38.2 
Trained staff on waste management 14 41.2 
Availability of SOPs for waste management 18 52.9 
Documentation of quantities of waste generated 12 35.3 
Separation of waste 24 70.6 
Use of recommended handling methods for Pharmaceutical waste 
(incineration above 1000°C, encapsulation, etc) 00 0.0 
Use of non-recommended disposal method e.g. 
(i) Open burning/burning below 1000°C 











pharmaceuticals nor their quantities in the wastewater is 
determined. For those that have effluent plants, the plants 
are mainly designed to remove sediments and pathogens 
before the wastewater is released into the environment.  
While developed countries may be exploring new 
technologies in treatment plants such as flocculation, 
ozonization, advanced oxidation, membrane filtration and 
photocatalysis to improve removal of pharmaceutical 
waste (Packer et al., 2003; Larsen et al., 2004; Zuccato 
et al., 2006), most developing countries such as Nigeria 
are yet to routinely pass wastewater through treatment 
plants before delivery into the lakes and rivers. 
 
 
Waste management practices 
 
Waste management requires the five pillars of 
management - planning, organizing, leading, co-
ordinating and monitoring for efficacy and effectiveness. 
Management of waste involves waste segregation, waste 
collection, waste transportation, waste storage, waste 
disposal, waste minimization and reuse (Townend and 
Cheeseman, 2005). The performance of the industries on 
waste management practices is shown in Table 3. 
Only 38.2% have policies on waste and three res-
pondents made it clear that they have health, safety and 
environmental policies. Waste separation was undertaken 
as claimed by 70.6%; however, on further probing, it was 
discovered that separation of waste was understood by 
some of the respondents as separation into solids and 
liquids. This could also imply that those who said they do 
not separate waste understood and sincerely admitted. 
More than 50% of the personnel, supposedly in charge of 
waste, were not trained to effectively manage waste. 
Those that were trained were either taught just the basics 
or had their training many years back and so were not 
aware of current trends in hazardous waste 
management. In most industries, it seemed the 
designated officers (quality assurance/control manager, 
production personnel, store man, compliance manager, 
gardener, etc) had waste management as an added 
portfolio and there was little or no supervision. It was only 
one industry that had a health, safety and environmental 
(HSE) officer. Three industries had waste management 
team comprising administration, quality assurance and 
production, while one of them had a more comprehensive 
team of production, quality assurance, finance, 
engineering and management or administration. The 
industry with a comprehensive team considers waste 
management as one of their priorities and so have perio-
dical environmental auditing to assess their strength and 
weakness as they implement their waste policy. 
It was also observed that those who claimed to have 
standard operating procedures (SOPs) do not have 
comprehensive SOPs on waste. Rather, they had SOPs 
on either cleaning or effluent water, microbial waste, 
waste disposal or handling of waste. The importers as-
sumed that since they are not manufacturers, they do not 
need SOPs on waste, though they generate waste. 
Although, 73.5% of the respondents are aware of the 
regulatory requirements on waste, most of them do not 
adhere to them.  
In reference to product recall, it was observed that 
32.4% did not have written recall procedures and those 
that recalled (35.3%) disposed the products improperly. 
Furthermore, as shown in Figure 3, most of the industries 
do not have disposal sites, while three respondents that 
had, undertook open burning on the sites and one had an 
incinerator. Waste, as well as treated waste, ought to be 
transported to a disposal site. The choice of disposal 
facilities is based on the type of treatment and the type of 
treatment can also affect the choice of disposal facilities 
(Nema and Gupta, 1999). 
Although, improper waste management practices were 
observed in over 90% of the industries visited, 58.8% of 
them had future plans for waste  which  included  building  










of incinerators, construction or upgrading of waste 
treatment plants, enforcement of health safety and 
environmental policies, recycling of wastewater, minimi-
zation of waste and operating standard treatment of 
waste. Immediate outcomes of this study were the 
awareness created and the promise of prompt action by 
the focal persons and management.  
 
 
Challenges to managing pharmaceutical waste 
 
From interactions with the respondents, it could be 
deduced that the regulatory bodies were not adequately 
trained and educated to influence the management of 
hazardous waste and were not aware that 
pharmaceutical waste is an emerging contaminant of 
major concern. This could also be an indicator to the fact 
that the federal and state governments are yet to make 
waste management a priority. The health of a country is 
the wealth of the country; consequently, pharmaceutical 
waste is detrimental to the health and wealth of the 
people. While developed countries are researching to 
provide techniques on how to manage emerging 
contaminants such as pharmaceuticals, developing 
countries such as Nigeria are attempting to tackle solid 
waste (which is bedevilled by poor management) and still 
deliberating on healthcare waste with little attention from 
the government.   
Although, regulatory authorities and ministries of 
environment have been set up, there are no indications 
that the regulatory bodies are fully equipped to function 
effectively. The pharmaceutical industries are not aware 
of any national policy on waste and some available 
guidelines are not specific on how to manage and 
dispose pharmaceutical waste. In fact, it appeared that 
Nigeria does not have a healthcare waste management 
policy and plan. Awareness is apparently lacking, 
although, one of the states (Lagos) has been having 
annual summits on waste management. However, lacks 
of training, monitoring and evaluation skills, storage and 
disposal facilities are major challenges to implementation. 
As the research on the effects of pharmaceutical waste 
on humans, quantification of the individual drugs, the 
synergistic effect or additives effects of the drugs, the 
right analytical techniques for assessment of 
pharmaceutical waste and the technology and cost of 
improving the treatment plant continues, one cannot but 
agree with Daughton who opined that the reality is to go 
back to the basics and prevent the entry of 
pharmaceuticals into the aquatic environment than try to 
determine their harmful effects at the expense of animals, 
time and finance. However, if the risks must be assessed, 




Conclusion and recommendations 
 
There is need to sustain the environment by standard and 
environmental friendly methods of managing waste so 
that we do not employ makeshift solutions for today’s 
problem, which will create greater problems for the next 
generations. Management of waste should be planned, 
documented, implemented and sustained. 
Most generators of hazardous waste are not aware of the 
health and environmental implications of improper 
disposal and so public awareness and training are 
imperative. Such training should be done for the staff of 
the regulatory authorities, the  key  players  in  the  public 





even the public. However, the level of training will differ 
with each group. 
As much as the regulatory authorities have been 
involved with treatment and disposal, management of 
waste should also include prevention and minimization. 
They should arise to their full responsibility of waste 
management. The regulatory bodies should not be in 
competition/fight over who is in charge of waste as 
reported by some respondents. Incineration rather than 
open burning should be employed and so incinerators 
with emissions control should be provided. 
Wastewater treatment plants with modern technologies 
such as ozonization and membrane filtration can be set 
up in the industrial estates to help those that cannot 
afford to own one. Services can be paid for by the 
industries to help with the maintenance of the plants. The 
treatment facilities should also be able to recycle water 
so that it can be fit for other purposes such as gardening. 
Industries should be supported to set up waste 
management teams, draft and implement waste 
management plans. There should be incentives, such as 
financial support, provision of industrial disposal units and 
free training of staff to encourage waste management. 
This will also diffuse the notion some respondents have 
about the regulatory authorities having levying it as its 
priority. Incentives are avenues for regulatory bodies to 
give back  to the industries and also a  means of 
motivating people to comply. The United States 
environmental protection agency's (U.S.EPA) program 
‘WasteWise’, which is a forum where the industries can 
share their activities and achievements on how they are 
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